Navigation Links
DOE laboratories help develop promising new cancer fighting drug, vemurafenib
Date:8/18/2011

DOE Laboratories Help Develop Promising New Cancer Fighting Drug, Vemurafenib

Powerful X-Rays Enable Development of Successful Treatment for Melanoma and Other Life-Threatening Diseases

WASHINGTON, DC Powerful X-ray technology developed at the U.S. Department of Energy's (DOE's) national laboratories is revealing new insights into diseases ranging from Alzheimer's to the swine flu, and, most recently, enabled the discovery of a groundbreaking new drug treatment for malignant melanoma, the deadliest form of skin cancer. The drug, Zelboraf (vemurafenib), received Food and Drug Administration (FDA) approval on Wednesday. In showing the structures of diseased and disease-causing molecules at their basic level, these extremely bright light sources enable scientists to suggest potential new treatments.

"This technology is a wonderful example of how innovations at our national laboratories lead to discoveries in a wide variety of fields," said Energy Secretary Steven Chu. "In this case, we are pleased to have been involved in research that has shown great promise in the battle against life-threatening melanoma."

An increasing number of drug discovery companies and medical researchers are turning to the powerful X-ray facilities at the DOE national laboratories to probe the causes of disease and develop new treatments. Researchers from Plexxikon Inc., the drug discovery company that developed the melanoma treatment, used X-ray light sources at three national laboratories SLAC National Accelerator Laboratory, Argonne National Laboratory and Lawrence Berkeley National Laboratoryto determine the specific, 3-D protein structure of a mutated enzyme that tells melanoma cancer cells to multiply uncontrollably.

The researchers used a technique called "macromolecular X-ray crystallography" to develop a drug that would prevent the enzyme from doing this. The newly FDA-approved drug, Zelboraf (vemurafenib), was extremely successful during clinical trials in disrupting the disease and extending the lives of those diagnosed with it.

"Plexxikon's drug discovery approach is critically dependent on harnessing the power of X-ray crystallography, and the role of DOE facilities in enabling the development of compounds like vemurafenib has been fundamental," said Gideon Bollag, Senior Vice President for Research at Plexxikon. "With the insight we gain from the three-dimensional structures, we have an atomic road map to rationally optimize our drug candidates."

In addition to this treatment for melanoma, the extremely bright light sources at these Office of Science labs have revealed new insights into diseases such as Alzheimer's disease, swine flu, autoimmune disorders, bird flu, hepatitis, and the common cold. In showing the structures of diseased and disease-causing molecular machines at their basic level, the tools for discovery enable scientists to suggest potential new treatments and offer brighter hopes for tomorrow.

The Department of Energy supports five of these advanced X-ray light sources, which are typically football field-sized installations optimized to produce precise, high intensity X-ray beams. Scientists from across the nation and around the globe are actively taking advantage of these scientific user facilities at the national laboratories to make discoveries in a diverse array of disciplines ranging from advanced energy research and materials science to biology and medicine.


'/>"/>

Contact: Jeff Sherwood
jeff.sherwood@hq.doe.gov
202-586-4940
DOE/US Department of Energy
Source:Eurekalert

Related medicine news :

1. The Helmholtz Association and Inserm create 2 joint research laboratories in France
2. MSD Wellcome Trust Hilleman Laboratories announces first project
3. Duke to lead oversight of HIV laboratories worldwide
4. ELLKAY Introduces Revolutionary Live Insurance Mapping Solution for Diagnostic Laboratories
5. Vinomis Laboratories Completes Additional Funding Round
6. Global Dental Laboratories Market to Exceed $14.5 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
7. Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories CRINONE(R) Progesterone Gel Product Line
8. IDEXX Laboratories Elects Joseph Vumbacco as Director
9. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
10. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
11. Common vein condition increases risk for developing life-threating blood clots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: